Xu He Selected Research

Insulin Resistance

4/2022	Purendan alleviates non-alcoholic fatty liver disease in aged type 2 diabetic rats via regulating mTOR/S6K1/SREBP-1c signaling pathway.
1/2022	Anti-diabetic and anti-obesity: Efficacy evaluation and exploitation of polyphenols in fruits and vegetables.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xu He Research Topics

Disease

43	Neoplasms (Cancer) 02/2022 - 05/2002
18	Hepatocellular Carcinoma (Hepatoma) 02/2022 - 04/2012
8	Venous Thrombosis (Deep-Vein Thrombosis) 01/2021 - 03/2009
8	Breast Neoplasms (Breast Cancer) 01/2020 - 05/2002
7	Thrombosis (Thrombus) 01/2022 - 03/2009
6	Lysosomal Storage Diseases (Lysosomal Storage Disease) 12/2019 - 01/2012
5	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 11/2008
5	Neoplasm Metastasis (Metastasis) 01/2021 - 05/2002
4	Inflammation (Inflammations) 01/2022 - 01/2018
4	Hypertension (High Blood Pressure) 01/2020 - 09/2013
4	Carcinogenesis 06/2015 - 09/2014
3	Pain (Aches) 06/2022 - 06/2012
3	Cataract (Cataracts) 01/2022 - 08/2017
3	Ischemia 01/2022 - 09/2015
3	Arteriovenous Fistula 06/2021 - 04/2019
3	Spinal Cord Injuries (Spinal Cord Injury) 01/2021 - 11/2018
3	Pathologic Constriction (Stenosis) 01/2020 - 02/2005
3	Mucopolysaccharidoses 12/2019 - 12/2013
3	Stomach Neoplasms (Stomach Cancer) 01/2019 - 11/2008
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018 - 02/2009
3	Esophageal Squamous Cell Carcinoma 01/2018 - 01/2009
3	Mucopolysaccharidosis I (Hurler Syndrome) 12/2017 - 01/2012
3	Autoimmune Diseases (Autoimmune Disease) 11/2014 - 03/2013
3	Inborn Genetic Diseases (Disease, Hereditary) 12/2013 - 01/2012
2	Hemorrhage 10/2022 - 02/2017
2	Mitochondrial Diseases (Mitochondrial Disease) 10/2022 - 01/2020
2	Insulin Resistance 04/2022 - 01/2022
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 04/2022 - 01/2018
2	Infections 01/2022 - 01/2021
2	Metabolic Diseases (Metabolic Disease) 01/2022 - 01/2020
2	Nephrotic Syndrome (Syndrome, Nephrotic) 01/2022 - 05/2010
2	Dry Eye Syndromes (Dry Eye Syndrome) 01/2022 - 01/2021
2	Adenocarcinoma of Lung 01/2022 - 02/2016
2	Varicose Veins (Varicose Vein) 01/2022 - 01/2021
2	Proteinuria 01/2022 - 01/2020
2	COVID-19 12/2021 - 05/2021
2	Pulmonary Embolism 04/2021 - 02/2011
2	Glomerulonephritis 01/2021 - 01/2020
2	Aneurysm (Aneurysms) 01/2021 - 01/2016
2	Neuroinflammatory Diseases 01/2021 - 11/2018
2	Thrombocytopenia (Thrombopenia) 01/2021 - 01/2015
2	Liver Neoplasms (Liver Cancer) 10/2020 - 01/2014
2	Chronic Kidney Failure (Chronic Renal Failure) 01/2020 - 04/2019
2	Emphysema 11/2019 - 06/2015
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2018 - 09/2014
2	Carcinoma (Carcinomatosis) 12/2016 - 07/2015
2	Melanoma (Melanoma, Malignant) 11/2016 - 04/2013
2	Hyperplasia 11/2014 - 02/2005

Drug/Important Bio-Agent (IBA)

12	Biomarkers (Surrogate Marker)IBA 04/2022 - 04/2012
10	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2002
8	Messenger RNA (mRNA)IBA 01/2020 - 05/2002
7	Pharmaceutical PreparationsIBA 02/2022 - 02/2005
6	AntigensIBA 01/2020 - 12/2016
6	Iduronidase (alpha-L-Iduronidase)IBA 12/2019 - 01/2012
6	Sorafenib (BAY 43-9006)FDA Link 12/2019 - 04/2012
6	EnzymesIBA 01/2018 - 05/2010
5	AutoantibodiesIBA 01/2020 - 12/2016
5	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 11/2019 - 05/2010
5	MicroRNAs (MicroRNA)IBA 01/2015 - 05/2013
4	Biological ProductsIBA 01/2022 - 11/2014
4	CytokinesIBA 01/2022 - 11/2014
4	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 11/2007
4	SurvivinIBA 01/2019 - 11/2008
4	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 11/2014 - 10/2012
3	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 01/2015
3	Tissue Plasminogen Activator (Alteplase)FDA Link 11/2019 - 01/2015
3	Type I DNA Topoisomerases (Topoisomerase I)IBA 01/2019 - 12/2016
3	ImmunosorbentsIBA 01/2018 - 05/2010
2	glubran 2IBA 10/2022 - 01/2021
2	LipidsIBA 04/2022 - 01/2022
2	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2020
2	AntibodiesIBA 01/2021 - 09/2013
2	alpha-Fetoproteins (alpha-Fetoprotein)IBA 10/2020 - 06/2013
2	Therapeutic UsesIBA 07/2020 - 09/2013
2	Phenobarbital (Luminal)FDA Link 04/2020 - 01/2020
2	SmokeIBA 11/2019 - 06/2015
2	Estrogen ReceptorsIBA 05/2019 - 06/2015
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2019 - 02/2005
2	Long Noncoding RNAIBA 01/2019 - 08/2018
2	Small Interfering RNA (siRNA)IBA 01/2018 - 09/2014
2	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 02/2017 - 05/2010
2	Peptides (Polypeptides)IBA 01/2017 - 03/2013
2	thiamine triphosphorate (TTP)IBA 06/2016 - 01/2014
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2014 - 05/2002
2	Telomerase (Telomerase Reverse Transcriptase)IBA 09/2014 - 12/2013

Therapy/Procedure

15	Therapeutics 02/2022 - 05/2010
8	Catheters 01/2022 - 07/2005
7	Stents 10/2020 - 02/2005
5	Thrombectomy 01/2022 - 03/2009
3	Immunotherapy 01/2022 - 05/2010
3	Renal Dialysis (Hemodialysis) 06/2021 - 02/2018
3	Enzyme Replacement Therapy 12/2017 - 01/2012
2	Punctures 06/2022 - 11/2014
2	Chinese Traditional Medicine (Traditional Chinese Medicine) 04/2022 - 01/2019
2	Vena Cava Filters (Inferior Vena Cava Filter) 01/2022 - 03/2009
2	Radiotherapy 05/2021 - 11/2019
2	Lasers (Laser) 01/2021 - 10/2017
2	Mesenchymal Stem Cell Transplantation 11/2019 - 06/2015
2	Radiofrequency Ablation 01/2018 - 12/2013
2	Phacoemulsification 10/2017 - 08/2017